Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Upgraded by BNP Paribas Exane

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by analysts at BNP Paribas Exane to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research report on Friday, May 8th. Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Six investment analysts have rated the stock with a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $23.95.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE:FMS opened at $24.89 on Tuesday. The company’s fifty day moving average price is $23.17 and its 200-day moving average price is $22.91. The firm has a market capitalization of $13.37 billion, a price-to-earnings ratio of 13.10, a PEG ratio of 4.40 and a beta of 0.78. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $27.64. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%. The firm had revenue of $5.34 billion for the quarter. On average, equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FMS. Pzena Investment Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% during the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after buying an additional 299,986 shares during the last quarter. Morgan Stanley lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after acquiring an additional 942,497 shares during the last quarter. Integral Health Asset Management LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after acquiring an additional 200,000 shares during the period. Moran Wealth Management LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 31.5% during the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock valued at $7,846,000 after acquiring an additional 83,311 shares during the period. Finally, Quantinno Capital Management LP grew its position in Fresenius Medical Care AG & Co. KGaA by 15.7% during the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after acquiring an additional 46,428 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.